The 5th U.S. Circuit Court of Appeals has overturned U.S. District Judge Matthew Kacsmaryk’s ruling which paused the availability of the abortion drug mifepristone. The ruling was in response to a lawsuit filed by pro-life groups which contends the drug was rushed into approval by the Food and Drug Administration (FDA) and that the FDA violated its own safety precautions. Under the Obama Administration, the FDA ruled that mifepristone could be dispensed through mail without an in-person doctor’s office visit. The 5th Circuit ruling reinstates the need for a doctor’s office visit and limits when the drug can be used. The case is expected to eventually go before the Supreme Court.